This article from Outsourced Pharma, offers a comprehensive roadmap to understanding key designations like Fast Track, Breakthrough Therapy, and Accelerated Approval, while highlighting the strategic questions sponsors must ask to determine eligibility.
It also emphasizes the critical role of experienced CDMO partners in managing technical, regulatory, and operational challenges, especially for rare and orphan diseases.
With the right collaboration, sponsors can align resources, mitigate risks, and bring life-changing therapies to patients faster.
Read the full article on the Outsourced Pharma.
